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Effect of shigatoxin-1 on arachidonate release by human glo- The pathogenesis of renal injury in postdiarrheal he-
merular epithelial cells. molytic uremic syndrome (HUS) has been hypothesized
Background. Altered arachidonic acid (AA) metabolism to be due, in large part, to shigatoxin (Stx) derived from
has been implicated in the pathogenesis of renal injury in the
enteric infection with Stx-producing strains of Escherichiahemolytic uremic syndrome (HUS). However, there is very
coli [1, 2]. Stx binds to galactose--1,4, galactose--1,4,little information of the effect of shigatoxin (Stx; the putative
glucose-ceramide (Gb3), is internalized, and ultimatelymediator of renal damage in HUS) on AA release or metabo-
lism by renal cells. Since recent studies have demonstrated that is cytotoxic, at least in part, by directly inhibiting peptide
glomerular epithelial cells (GECs) may be important early elongation [3]. Stx may also exert pathologic effects by
targets of Stx, the current study was undertaken to examine altering a variety of factors involved in regulation ofthe effects of Stx on AA release and metabolism by GECs.
vascular tone, thrombosis, and inflammation [3]. AmongMethods. Cultured human GECs were exposed to Stx1 
these factors, arachidonic acid (AA) metabolites havelipopolysaccharide (LPS) for 4 to 48 hours followed by determi-
nation of 3H-arachidonate release, thromboxane A2 (TxA2) and been frequently invoked. Elevated urinary thromboxane
prostacyclin (PGI2) production, cyclooxygenase (COX) activ- A2 (TxA2), a vasoconstrictor, has been described in pa-
ity, and Western and Northern analyses for phospholipase A2 tients with HUS [4]. Decreased cellular release of prosta-
(PLA2) and COX protein and mRNA levels, respectively. cyclin (PGI2), a vasodilator and antithrombotic factor,Results. Stx1 increased arachidonate release by GECs. LPS
has been reported in patients with HUS [5]. In addition,alone had no such effect, but increased arachidonate release
red blood cell [6] and blood vessel [5] AA levels havein response to Stx1. Stx1-stimulated arachidonate release corre-
lated with elevations in cPLA2 and sPLA2 protein and cPLA2 been reported to be reduced in patients with HUS. De-
mRNA levels. Stx1 also increased both TxA2 and PGI2 produc- spite these studies, there is very little information on the
tion by GECs; LPS alone did not alter eicosanoid production, direct cellular effects of Stx on AA metabolism, particu-
but augmented Stx1 effects. Both Stx1 and LPS stimulated COX larly in the kidney. Such information would be importantactivity; however, these effects were not additive. Although there
since AA potentially could exert a wide variety of patho-was an accompanying elevation of COX-1 and COX-2 mRNA,
logic renal effects in HUS. For example, free AA can beStx1 decreased and LPS did not change COX1 and COX2 pro-
tein levels. incorporated into the cellular membrane, act as a second
Conclusions. Stx1 alone or in conjunction with LPS in- messenger, or be metabolized by a variety of enzymes such
creases arachidonate release and eicosanoid production by hu- as cyclooxygenase (COX), lipoxygenase, or cytochrome
man GECs; this effect correlates with increased PLA2 protein p450 [7–9]. Free AA can alter ion channel conductanceand mRNA levels. To our knowledge, this is the first study
and intracellular communication via gap junctions [10–12];identifying the mechanisms of Stx1-stimulated AA release.
activate protein kinase C and mitogen-activated proteinThese results raise the possibility that arachidonate release and
metabolism by GECs, and conceivably other renal cell types, kinase isoforms, resulting in a myriad of cellular effects
are involved in renal injury in HUS. [13, 14]; modify gene transcription [15–17]; and induce a
variety of inflammatory reactions [18–21]. Thus, informa-
tion on the direct effect of Stx on renal cellular AA pro-
1 See Editorial by Kaplan, Myers, and Leonard, p. 1199 duction and metabolism would be potentially important.
Several cell types could be involved in the renal re-Key words: hemolytic uremic syndrome, thromboxane, prostaglandin,
phospholipase, cyclooxygenase, renal injury. sponse to Stx. Glomerular endothelial cell swelling and
detachment are prominent in established HUS renal in-Received for publication September 27, 2000
jury [3], suggesting that these cells are important targetsand in revised form April 3, 2001
Accepted for publication April 11, 2001 of Stx. This conclusion is confounded, however, by the
finding that cultured human glomerular endothelial cells 2001 by the International Society of Nephrology
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have low intrinsic sensitivity to shigatoxin-1 (Stx1) and from Amersham (Arlington Heights, IL, USA). Dyna-
beads were from Dynal (Lake Success, NY, USA). Mousethat Stx1 cytotoxicity in these cells may be dependent
on inflammatory cytokines [22]. There is also evidence anti-human -actin and 3H-AA were from ICN Bio-
chemicals (Aurora, OH, USA), and primary antibodies,that renal epithelial cells are targets of Stx. For example,
human renal cortical tubular epithelial cells express including sheep anti-human COX-1, rabbit anti-human
cPLA2 (cytosolic phospholipase A2), mouse anti-humanabundant Gb3 [23], while kidneys from patients with
HUS in its early stages reveal histologically apparent sPLA2 (secretory PLA2), and sPLA2 electrophoretic
standard were from Cayman Chemical (Ann Arbor, MI,proximal tubular damage [24]. Furthermore, recent stud-
ies have found that cultured human glomerular epithelial USA). The COX-2 primary antibody was a kind gift of
Dr. Steven Prescott (University of Utah, Salt Lake City,cells (GECs) and human proximal tubule cells [25] con-
tain large amounts of Gb3 and are highly sensitive to UT, USA). Stx1 was isolated in our laboratory by passing
bacterial lysate over a Gb3-coated column as previouslythe cytotoxic effects of Stx1 under basal (noncytokine
stimulated) conditions [26]. This raises the possibility described [30]. All other chemicals were obtained from
Sigma (St. Louis, MO, USA) unless otherwise indicated.that Stx interaction with epithelial cells occurs in the
early stages of HUS and that such interaction could
Epithelial cell culturesevoke cellular responses that promote subsequent renal
injury. As stated previously in this article, elaboration Human GECs were isolated and characterized as pre-
viously described [26]. Briefly, cortical tissue was ob-of AA by these cells, with the potential to promote cell
injury, alter hemodynamics, alter platelet aggregation, tained from the normal pole of kidneys removed due to
renal cell carcinoma. Glomeruli were obtained by sievingand promote inflammation (with elaboration of inflam-
matory cytokines that might alter Gb3 expression by and digested with 1 mg/mL of collagenase (type IV;
Sigma) until reduced in size by 50 to 75%. Glomerularneighboring cells), could be an important early event.
Consequently, the first aim of this study was to examine remnants were suspended in GEC media [M199  20%
FBS  100 g/mL ECGS  heparin (90 g/mL)  P/S]Stx modulation of AA release and metabolism by renal
epithelial cells. Since GECs are located close to glomeru- and plated onto gelatin-coated 10 cm tissue culture
dishes. Cells were trypsinized and passaged when ap-lar endothelial cells and have the potential to modify
their biology, GECs were chosen for these initial studies. proximately 40% confluent. All cells were studied after
no more than four passages. Cultures were maintainedIn addition to Stx, lipopolysaccharide (LPS) is likely
to be present in the circulation of HUS patients [27, 28]. at 37C in a 5% CO2 environment.
Immunofluorescent staining was performed using pri-LPS alone does not cause HUS; however, several studies
have demonstrated that LPS augments the cytotoxic ef- mary anti-human antibodies, including mouse anti-factor
VIII-related antigen (Boehringer Mannheim, Indianap-fects of Stx1 on a variety of cell types [22, 25, 29]. Hence,
the possibility exists that LPS could potentiate the effects olis, IN, USA), mouse anti-PECAM-1, mouse anti-E-
selectin and mouse anti-vimentin (R&D Systems, Min-of Stx on GEC. LPS can modify enzyme activity within
the AA metabolic cascade in some cell types; however, neapolis, MN, USA), mouse anti-cytokeratin 18, mouse
anti-cytokeratin 19, mouse anti-pan cytokeratin (reactsits effects on human GEC arachidonate release and eico-
sanoid synthesis, either alone or in combination with poorly with cytokeratin 18 and not with 19; all from
Sigma), rabbit anti-WT-1 (Santa Cruz, Santa Cruz, CA,Stx1, are unknown. Thus, the second aim of this study
was to examine the effect of LPS, either alone or with USA), and mouse anti-myosin (Accurate, Westbury,
NY, USA). Secondary antibodies were mouse anti-rabbitStx1, on AA release and metabolism by GECs.
IgG (Sigma) and rabbit anti-mouse IgG (Boehringer
Mannheim). Primary cultures of human umbilical vein
METHODS
endothelial cells (HUVECs; kindly provided by Dr. Tom
Reagents McIntyre, University of Utah, Salt Lake City, UT, USA),
human mesangial cells (HMCs), and human proximalMedia M199, penicillin/streptomycin (P/S), gentami-
cin, l-glutamine, mouse Maloney leukemia virus-reverse tubular cells (HPT; Clonetics, San Diego, CA, USA)
were used as controls for immunofluorescent staining.transcriptase, Superscript II, Oligo dT, dNTPs, SP6 and
T7 RNA transcriptases and Taq DNA polymerase were Freshly isolated human glomeruli also served as controls.
Confluent GEC cultures were growth arrested inobtained from GIBCO (Grand Island, NY, USA). Endo-
thelial cell growth supplement (ECGS) was from Intracel M199 5% FBS P/S (growth-arrest media) except for
experiments measuring TxA2 or PGI2; these were growth(Rockville, MD, USA). Fetal bovine serum (FBS) was
from Hyclone Laboratories (Logan, UT, USA). Radio- arrested in M199  100 g/mL ECGS  90 g/mL
heparin P/S (FBS interferes with the RIA). Cells wereimmunoassay (RIA) kits for thromboxane B2 and 6-keto-
prostaglandin F1, horseradish peroxidase-conjugated growth arrested 24 hours before initiating experimental
conditions.donkey anti-rabbit IgG and sheep anti-mouse IgG were
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Determination of arachidonic acid night at 4C in TBST (20 mmol/L Tris-HCl, pH 7.6, 137
mmol/L NaCl, 0.1% Tween-20) 5% nonfat dry milkrelease and metabolism
5% donkey serum  1% sheep serum. The primary anti-For estimating PLA2 activity, GECs were incubated
body in blocking buffer was added to blots for one hour.with 0.5 Ci/mL 3H-arachidonate in experimental media
Blots were rinsed in blocking buffer, and the horseradish(M199  5% FBS  10 mol/L indomethacin  100
peroxidase-linked secondary antibody (in TBST  5%U/mL P/S) for one hour. Stx1  LPS in experimental
donkey serum  1% sheep serum) was added for onemedia was then added for 4, 24, or 48 hours. The cells
hour. Membranes were rinsed and bands detected bywere washed and M199 containing 1% fatty-acid free
chemiluminescence (Santa Cruz Biochemicals). Auto-bovine serum albumin (BSA) and 10mol/L indometha-
radiography was performed, and densitometry of thecin was added for 30 minutes, followed by determination
acquired images was measured with an Eagle Eye II gelof 3H-arachidonate released into the culture medium
documentation system and analyzed using Scanalyticsusing a beta counter (Beckman Coulter, Fullerton, CA,
software (Stratagene, La Jolla, CA, USA).USA). Radioactivity was also measured in a small aliquot
of protein to measure total cellular 3H-arachidonate. Cloning and riboprobe synthesis
Glomerular epithelial cells were treated with Stx1 (10
A plasmid containing an insert corresponding to thepg/mL to 10 ng/mL)  LPS (1 g/mL) or LPS alone for
5-untranslated region of COX-2 mRNA was a kind gift of4, 24, or 48 hours. Media were assayed by RIA, according
Dr. Chris Maloney (University of Utah). All other plasmidsto the manufacturer’s directions, for TxB2 or 6-keto- were prepared as follows: Oligo dT primed, first-strandprostaglandin F1, the stable metabolites of TxA2 and complementary DNA (cDNA) was prepared from totalPGI2, respectively. Total protein as measured by the cellular RNA isolated from LPS-treated HUVEC usingBradford method was used to normalize the data [31].
Superscript II reverse transcriptase. Polymerase chainFor cyclooxygenase activity determination, growth-
reaction (PCR) was performed on RNA from LPS-stim-arrest media containing Stx1  LPS or LPS alone was
ulated HUVECs using the following primers: cPLA2 (486added to the cells for 4, 24, or 48 hours. Media were
bp product), forward, 5-GCC CTT TAC CTC TTT TCA
then removed, and cells were rinsed with M199. M199 
CCT G-3, reverse, 5-CGA CGT CCT TCT CTG GTA
0.1% BSA containing a saturating (determined in pre- TTG-3; COX-1 (521 bp product), forward, 5-GTG CTG
liminary experiments) concentration of unlabeled ara- GAT GGA GAA ATG TAC-3, reverse, 5-GGT GTT
chidonate (50 mol/L) was added to the cells for 30 GAA CAA GAA CTG CTC G-3; and GAPDH (586 bp
minutes, at which time media were removed and TxB2 product), forward, 5-GTG AAG GTC GGT GTC AAC
was assayed by RIA. GGA TTT-3, reverse, 5-CAC AGT CTT CTG AGT
GGC AGT GAT-3.Western blot analysis
Purified (Magic PCR Prep; Promega, Madison, WI,
Glomerular epithelial cells were treated with Stx1  USA) and sequenced PCR products were then cloned
LPS for 4, 24, or 48 hours. As production of all enzyme into a pGEM-T vector (Promega) and subjected to di-
isoforms to be studied has been reported to be stimulated deoxynucleotide sequence analysis. JM109 cells were
in HUVECs by LPS, LPS (1 g/mL)-treated HUVECs transfected with the plasmids and an antisense RNA
served as positive controls. Cells were lysed and centri- probe (riboprobe) synthesized using a RiboProbe In
fuged for five minutes at 14,000 g, and the supernatant Vitro Transcription System (Promega) to a specific activ-
was retained and diluted to a protein concentration of ity of 109 cpm/g.
1 mg/mL. Sample loading buffer was added to the protein
Northern blot analysismixture. Samples were denatured by heating at 90C
for five minutes, placed on ice, and either loaded onto Total RNA was isolated using guanidine thiocyanate-
polyacrylamide gels or stored at 	70C. phenol-chloroform extraction. Total RNA (20 g) was
Electrophoresis was done using a minigel apparatus loaded on a 0.9% agarose–0.66 mol/L formaldehyde gel,
(Mini-Protean II; Bio-Rad, Hercules, CA, USA). Sam- electrophoresed, transferred to Hybond N membranes,
ples (30 g) were electrophoresed on a 5% stacking and ultraviolet cross-linked. Membranes were prehy-
gel [29:1 acrylamide:bis-acrylamide solution, 125 mmol/L bridized with 50% formamide, 5 standard saline citrate
Tris-HCl, pH 6.8, 0.1% sodium dodecyl sulfate (SDS), (SSC), 5  Denhardt’s solution, 1% SDS, and 1 g/mL
0.1% ammonium persulfate, 1 L/mL tetramethylethy- denatured salmon sperm DNA for four hours at 60C.
lenediamine (TEMED)], separated on a 10% resolving The riboprobe was added to the hybridization buffer for
gel (29:1 acrylamide:bis-acrylamide solution, 375 mmol/L 72 hours at 60C. Each membrane was probed using one
Tris-HCl, pH 8.8, 0.1% SDS, 0.1% ammonium persul- specific riboprobe at a time. GAPDH was used to control
fate, 0.5 l/mL TEMED) and transferred onto Hybond- for RNA integrity and to normalize the data, and the
GAPDH riboprobe was only added after densitometryECL immobilon membranes. Blots were blocked over-
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Fig. 1. Effect of shigatoxin-1 (Stx1) and lipo-
polysaccharide (LPS) on prostacyclin produc-
tion by glomerular epithelial cells (N 
 6 for
each data point). *P  0.01 vs. controls; #P 
0.05 vs. Stx1 10 pg/mL at same time point;
†P  0.01 vs. Stx1 10 pg/mL at same time
point. Bar indicates significance at time points
covered. Control levels of prostacyclin were
17.7  1.1 pg/mg total cell protein. Symbols
are: () 4 hours; () 24 hours; ( ) 48 hours.
was done on the primary product. No membranes were increased after 24 hours of exposure to Stx1 (Fig. 2).
This increase was also time- and dose-dependent in asubjected to stripping. Blots were rinsed with 0.1 
SSC  0.1% SDS at temperatures up to 80C as needed manner similar to that seen with PGI2 production. LPS
alone did not alter production of TxA2; however, LPSto remove nonspecific binding. Densitometry was per-
formed using a Bio-Rad phosphorimaging system and augmented Stx1 effects on TxA2 production. Lower con-
centrations of Stx1 (100 fg/mL to 1 pg/mL) did not stimu-Quantity One software. Conventional autoradiography
was also performed. late eicosanoid release by GEC (data not shown).
Effect of Stx1  LPS on PLA2 activityStatistics
Data are presented as mean values (SEM) with N Increases in TxA2 and PGI2 occurred at similar times
and to similar degrees, suggesting that Stx1 increasesreferring to the number of samples measured for each
data point. All data were analyzed using one-way analy- production of these prostanoids by up-regulating enzy-
sis of variance (ANOVA,  
 0.05) and evaluated by matic activity at a point common to both TxA2 and PGI2
the Student t test after Bonferroni correction. Values biosynthetic pathways. The effect of Stx1LPS on PLA2
were taken to be significant if P  0.05. activity, a measure of arachidonate release, was then
assessed. Stx1 at 10 ng/mL was used since this concentra-
tion clearly stimulated TxA2 and PGI2 release by GECs.RESULTS
Shigatoxin-1 increased arachidonate release by GECs,
Effect of Stx1  LPS on eicosanoid with a minimal effect noted at four hours and a progres-
production by GEC sive increase up to 48 hours (Fig. 3). LPS alone did not
affect arachidonate release, but significantly augmentedTo estimate the effects of Stx1  LPS on the AA
cascade, we measured the production of COX metabo- the Stx1 response at all time points. To determine
whether elevated arachidonate release reflected an in-lites, PGI2, and TxB2. Stx1 concentrations and exposure
times were based on previous studies and were selected crease in PLA2 enzyme abundance and/or mRNA levels,
Western and Northern analyses were performed. Twoso that there was either no (10 pg/mL for up to 24 hours
[26]) or minimal (10 ng/mL for 24 hours causes 15% major PLA2 isoforms, cPLA2 and sPLA2, were evaluated.
With regards to cPLA2, a predominant band at 70 kD wasGEC death [26]) cytotoxicity. Stx1 increased GEC bio-
synthesis of PGI2 in a time- and dose-dependent manner, apparent on Western analysis (Fig. 4A). Densitometry of
the 70 kD band revealed an increase in cPLA2 proteinwith the effect first being evident at 24 hours (Fig. 1).
LPS alone did not alter PGI2 production but significantly in response to Stx1 at 48 hours (Fig. 5A). LPS alone
slightly increased cPLA2 protein levels at 24 hours andaugmented the effects of Stx1. TxA2 levels were also
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Fig. 2. Effect of shigatoxin-1 (Stx1) and lipo-
polysaccharide (LPS) on thromboxane A2
(TxA2) production by glomerular epithelial
cells (N 
 6 for each data point). *P  0.05
vs. controls; **P 0.05 vs. controls; †P 0.01
vs. Stx1 alone (10 ng/mL) at the same time
points; #P 0.01 vs. LPS alone. Control levels
of thromboxane were 716  20 pg/mg total
cell protein. Symbols are: () 4 hours; () 24
hours; ( ) 48 hours.
Fig. 3. Effect of shigatoxin-1 (Stx1) (10 ng/
mL) and lipopolysaccharide (LPS) (1 g/mL)
on arachidonate release by glomerular epithe-
lial cells (N 
 12 for each data point). *P 
0.05 vs. controls; †P 0.05 vs. Stx1; #P  0.05
vs. LPS alone. Symbols are: () 4 hours; ()
24 hours; ( ) 48 hours. Bars indicate signifi-
cance for all time points covered by the bar.
augmented Stx1 action at 24 to 48 hours. cPLA2 mRNA samples revealed only a 48 kD band (data not shown).
Consequently, the optical density of both bands was usedmigrated at 3.7 kb on a denaturing gel (Fig. 4B); densi-
tometry on this band revealed that Stx1 increased cPLA2 in determination of sPLA2 protein levels. Stx1 increased
sPLA2 protein at 24 hours (Fig. 6). Notably, the increasemRNA levels at 12 and 24 hours (Fig. 5B). LPS also
increased cPLA2 levels (24 hours); however, LPS did not occurred in both the 48 kD and 75 kD bands (data not
shown). LPS increased sPLA2 protein at 4 and 24 hours,augment Stx1 action on cPLA2 mRNA.
The other PLA2 isoform examined, sPLA2, migrated at but had a minimal effect on Stx1-stimulated sPLA2 pro-
tein levels.48 and 75 kD on SDS-polyacrylamide gel electrophoresis
(SDS-PAGE; Fig. 4A). A purified 14 kD sPLA2 electro- The sPLA2 antibody for Western blotting was raised
against the type II PLA2 isoforms [33], which have beenphoretic standard also migrated at 48 kD. The 75 kD
band may be due to sPLA2 multimers forming in frozen strongly implicated in the PLA2 inflammatory response.
Despite this, reverse transcription-polymerase chain re-protein samples that are stored in SDS and dithiothreitol
(DTT) [32]. Notably, sPLA2 blots performed on fresh action (RT-PCR) using multiple primer sets directed
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Fig. 4. Western (A) and Northern (B) blots of
PLA2 and COX isoforms in GECs. Blots are
shown from samples treated for 24 hours with
Stx1 (10 ng/mL). Abbreviations are: cPLA2,
cytosolic phospholipase A2; sPLA2, secretory
phospholipase A2; COX-1 and -2 cyclooxygen-
ase; and GAPDH, glyceraldeyhde-3-phos-
phate dehydrogenase. Lanes shown are dupli-
cate (A) or triplicate (B) measurements.
toward type IIA PLA2 mRNA yielded no products in latory effect (Fig. 9B). In addition, LPS increased COX-2
either LPS-stimulated HUVECs or Stx1-treated GECs mRNA levels in conjunction with Stx1; however, this
(data not shown). Primers were also synthesized for other effect was less than that seen with LPS alone.
recently characterized PLA2 isoforms (type IID, V, and
X PLA2) that were derived from known sequences (Gene- DISCUSSIONBank) and from published reports [34–39]. None of the
Arachidonic acid can exert a multitude of effects onprimers directed at type IID, V, or X yielded PCR prod-
a variety of cell types [8, 9, 15, 18, 20, 21, 40]. Becauseucts.
of these effects, together with the potentially deleterious
Effect of Stx1  LPS on COX activity in GECs effects of AA metabolites [3, 4, 34] and because GECs
are exquisitely sensitive to Stx1 [26, 41], we examinedThe other enzyme family common to PGI2 and TxA2
whether Stx1 directly stimulates release of AA fromsynthesis is the COXs. Having demonstrated increased
GECs. This study reports that Stx1 stimulates free ara-eicosanoid production and arachidonate release, the Stx1
chidonate release from GECs. Such Stx1-enhanced ara-LPS effects on overall COX activity were assessed. COX
chidonate release may, in and of itself, be injurious. Un-activity increased in response to Stx1 in a time-depen-
esterified AA can modify ion channel conductances anddent manner (Fig. 7). Although LPS increased COX
intracellular communication via gap junctions [11, 12, 42].activity by itself, the effect was gone by 48 hours, and
AA can activate protein kinase C and mitogen-activatedit did not augment Stx1 action. To determine whether
protein kinase isoforms [13, 14], induce apoptosis [43, 44]elevated COX activity reflected an increase in enzyme
and modify gene transcription, most notably that of heatabundance and/or mRNA levels, Western and Northern
shock proteins [15–17]. AA can also stimulate chemotaxis,blot analyses were performed on the two COX isoforms,
superoxide anion formation, degranulation, and adhe-COX-1 and COX-2.
sion molecule expression in neutrophils [18–21, 45–47],Cyclooxygenase-1 protein migrated at 75 kD on SDS-
suggesting an interaction between glomerular cells andPAGE (Fig. 4A). Stx1 decreased COX-1 protein levels
neutrophils that potentially could result in renal injury.in a time-dependent manner, while LPS had no effect
Although unesterified AA is likely to be metabolized(Fig. 8A). In contrast, Stx1 markedly increased COX-1
quickly or reincorporated into membrane phospholipids,mRNA levels (migrated at 2.8 kb; Fig. 4B) at both 12
the effective AA concentration within the glomerularand 24 hours (Fig. 8B). LPS alone also increased COX-1
microenvironment could reach levels capable of trig-mRNA levels at 12 hours (Fig. 8B); however, LPS re-
gering these effects.duced Stx1-augmented COX-1 mRNA levels.
Our study also reports that Stx1 increases both TxA2Cyclooxygenase-2 protein migrated at approximately
and PGI2 production by cultured human GECs. The70 kD on SDS-PAGE (Fig. 4A). Densitometry on this
significance of this observation in terms of its implica-band indicated that Stx1 decreased COX-2 protein levels
tions for renal damage in HUS is uncertain. TxA2 andwhile LPS had no effect (Fig. 9A). Stx1 did not signifi-
cantly alter COX-2 mRNA levels, while LPS had a stimu- PGI2 generally have opposing effects on vascular tone
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Fig. 5. Effect of shigatoxin-1 (Stx1) (10 ng/
mL) and lipopolysaccharide (LPS) (1 g/mL)
on cytosolic phospholipase A2 (cPLA2) pro-
tein and mRNA levels in glomerular epithelial
cells. (A) Densitometry of cPLA2 Western
blot data (N
 4 for each data point). Symbols
are: () 4 hours; () 24 hours; ( ) 48 hours.
(B) Densitometry of cPLA2 Northern analysis
(N 
 3 for each data point). Symbols are: ()
12 hours; () 24 hours. *P  0.05 vs. control;
**P  0.05 vs. Stx1 alone at same time point;
†P  0.05 vs. LPS at same time point.
and thrombosis [48]. As noted previously in this article, Hence, the major conclusion that can be drawn from the
current study is that Stx1, by virtue of stimulating freefree AA may be deleterious per se and increased eicosa-
noid production may be of relatively modest biologic arachidonate accumulation in GECs, may have the po-
tential to significantly impact renal function in the settingsignificance. Such speculations must be tempered, how-
ever, by concerns over extrapolating in vitro patterns of of HUS.
The Stx1-stimulated arachidonate release was associ-AA metabolism to in vivo conditions. In addition, AA
released by Stx could be metabolized by the p450 path- ated with increased sPLA2 and cPLA2 protein content
at 24 and 48 hours, respectively, suggesting that thisway into a variety of inflammatory and vasoconstrictive
substances. While such detailed investigation of the pre- effect is due, at least in part, to increased PLA2 activity
and protein levels. Furthermore, Stx1 increased cPLA2cise metabolic fate of Stx1-stimulated AA in GECs was
beyond the scope of the current study, it is important to mRNA over a time course similar to that observed with
induction of cPLA2 protein, suggesting that increasedemphasize that there are a plethora of AA metabolites
that have the potential to affect renal biology in HUS. cPLA2 protein levels reflect enhanced gene transcription
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Fig. 6. Effect of shigatoxin-1 (Stx1) (10 ng/
mL) and lipopolysaccharide (LPS) (1 g/mL)
effect on secretory phospholipase A2 (sPLA2)
protein levels in glomerular epithelial cells.
Data shown are from densitometry of sPLA2
Western blot data (N
 4 for each data point).
Symbols are: () 4 hours; () 24 hours; ( )
48 hours. *P  0.05 vs. controls.
Fig. 7. Effect of shigatoxin-1 (Stx1) (10 ng/mL)
and lipopolysaccharide (LPS) (1 g/mL) on
COX activity in glomerular epithelial cells (N

6 for each data point). Symbols are: () 4 hours;
() 24 hours; ( ) 48 hours. *P  0.01 vs.
controls; **P  0.05 vs. controls; #P  0.05
vs. Stx1 alone at same time point; †P  0.05
vs. LPS alone at same time point.
with resultant increased mRNA translation. We were 24 to 48 hours of exposure to the toxin and that enhanced
protein synthesis is most likely involved.unable to detect type II PLA2 mRNA in GEC under
any conditions and using multiple primer sets. This was Shigatoxin-1 also increased COX activity in GECs;
however, this effect was associated with substantial de-surprising since the antibody utilized for Western analy-
sis was raised against type II PLA2 [33]. In addition, no creases in total COX-1 and COX-2 protein content. Since
the amount of active COX protein was not directly as-type IID, IB, V, or X PLA2 mRNA could be detected
in GECs by RT-PCR. Hence, it is not possible at this sessed, it is unknown whether Stx1 increases the amount
of active [49], while decreasing the total, COX protein orpoint to be certain as to the role of sPLA2 in Stx1-
stimulated arachidonate release in GECs. Nonetheless, whether another, as yet unidentified protein with COX
activity, is involved. Proteins with COX activity otherit is clear that Stx1 markedly stimulates arachidonate
release from GECs, that this effect is most evident after than COX-1 and COX-2 have not, to our knowledge,
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Fig. 8. Effect of shigatoxin-1 (Stx1) (10 ng/mL) and lipopolysaccharide Fig. 9. Effect of shigatoxin-1 (Stx1) (10 ng/mL) and lipopolysaccharide
(LPS) (1 g/mL) on COX-1 protein and mRNA levels in glomerular (LPS) (1 g/mL) on COX-2 protein and mRNA levels in glomerular
epithelial cells. (A) Densitometry of COX-1 Western blot data (N 
 epithelial cells. (A) Densitometry of Western blot data (N 
 4 for each
4 for each data point). Symbols are: () 4 hours; () 24 hours; ( ) 48 data point). Symbols are: () 4 hours; () 24 hours; ( ) 48 hours. (B)
hours. (B) Densitometry of COX-1 Northern analysis. Symbols are: Densitometry of COX-2 Northern blot analysis (N 
 3 for each data
() 12 hours; () 24 hours. *P  0.01 vs. controls; **P  0.05 vs. point). Symbols are: () 12 hours; () 24 hours. *P  0.05 vs. control;
controls; †P  0.05 vs. LPS. #P  0.05 vs. Stx1  LPS.
been identified. Stx1 also augmented COX-1, but not as that seen with Stx1 alone; however, LPS did not en-
hance arachidonate release. This indicates that Stx1 stim-COX-2, mRNA levels in GECs. The fall in COX-1 pro-
tein in the face of increased COX-1 mRNA suggests ulation of arachidonate release is not merely a reflection
of PLA2 protein levels, but also must relate to enzymethat Stx1 inhibits translation of COX-1 mRNA and/or
accelerates existing COX-1 protein degradation. Exami- activation.
Lipopolysaccharide did enhance the stimulatory effectnation of these various possibilities, however, was be-
yond the scope of the current study. of Stx1 on TxA2 and PGI2 by GECs. This effect was
associated with increases in both arachidonate releaseThe current study also investigated the effects of LPS
on GEC arachidonate metabolism since the endotoxin and cPLA2 protein levels. LPS and Stx1 together had a
smaller stimulatory effect on COX-1 mRNA accumula-is likely to be present in the circulation of patients with
HUS [27, 28]. Although LPS has been shown to activate tion as compared to Stx1 alone and also had a smaller
stimulatory effect on COX-2 mRNA accumulation asthe AA metabolic cascade [50, 51], LPS alone did not
stimulate production of TxA2 and PGI2 by GECs. LPS compared with LPS alone; the reasons for these differ-
ences are unknown.did have a very modest stimulatory effect on COX activity
that was associated with increased COX-1 and COX-2 In conclusion, our study demonstrates that Stx1 stimu-
lates arachidonate release by GECs and that this effectmRNA levels, an effect that has been noted in other
cell types [51–54]. In addition, the endotoxin increased is associated with increased PLA2 activity, protein, and
mRNA levels. LPS alone had no effect alone, but aug-cPLA2 and sPLA2 protein levels to a comparable degree
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messenger role for unsaturated fatty acids: Activation of Ca2-ments Stx-stimulated arachidonate release by GECs. In
dependent protein kinase. Science 224:622–625, 1984
addition, Stx stimulates both TxA2 and PGI2 by GECs; 14. Asaoka Y, Nakamura S, Yoshida K, et al: Protein kinase C,
calcium and phospholipid degradation. Trends Biochem Sci 17:414–this effect is augmented by LPS. These findings raise the
417, 1992possibility that GEC-derived arachidonate and subse-
15. Tebbey PW, Buttke TM: Independent arachidonic acid-mediated
quent activation of the AA metabolic cascade play a role gene regulatory pathways in lymphocytes. Biochem Biophys Res
Commun 194:862–868, 1993in the glomerular pathology observed in HUS.
16. Jurivich DA, Sistonen L, Sarge KD, et al: Arachidonate is a
potent modulator of human heat shock gene transcription. Proc
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